Physician profile
Carl B Anders
NPI 1194779843
$1,128.41
in general payments reported to CMS, 2019-2025
20 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2023: $43.90 · 2024: $373 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $236.74 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $126.09 | 2019-2025 | |
| Abbvie INC. | $120.38 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $90.16 | 2019 | |
| Glaxosmithkline, LLC. | $89.40 | 2023-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $61.73 | 2019-2024 | Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $52.00 | 2024-2025 | |
| Astellas Pharma US INC | $42.11 | 2019 | |
| Amgen INC. | $40.26 | 2019-2024 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $38.94 | 2025 | Eliquis |
| Novo Nordisk INC | $37.70 | 2019-2025 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $27.12 | 2024 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $25.06 | 2024 | Spravato |
| Shire North American Group INC | $24.93 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.02 | 2025 | Gardasil 9, Capvaxive |
| Teva Pharmaceuticals USA, INC. | $16.66 | 2019 | |
| Currax Pharmaceuticals LLC | $14.32 | 2025 | Contrave |
| Ars Pharmaceuticals Operations, INC. | $13.67 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Anders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.